Comparing Days of Therapy (DOT) and Defined Daily Doses (DDD) as Risk Factors for Antimicrobial Resistance in a Multi-Level Model

[1]  R. Leclercq,et al.  Hospital-wide modification of fluoroquinolone policy and meticillin-resistant Staphylococcus aureus rates: a 10-year interrupted time-series analysis. , 2011, The Journal of hospital infection.

[2]  D. Nicolau,et al.  Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem. , 2011, The Journal of antimicrobial chemotherapy.

[3]  P. Astagneau,et al.  Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France. , 2011, The Journal of hospital infection.

[4]  J. Schrenzel,et al.  Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. , 2011, The Journal of antimicrobial chemotherapy.

[5]  Evangelos I. Kritsotakis,et al.  Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. , 2011, The Journal of antimicrobial chemotherapy.

[6]  Samir N. Patel,et al.  New Delhi Metallo-β-Lactamase, Ontario, Canada , 2011, Emerging infectious diseases.

[7]  P. Davey,et al.  Clinical Impact of Antimicrobial Resistance in European Hospitals: Excess Mortality and Length of Hospital Stay Related to Methicillin-Resistant Staphylococcus aureus Bloodstream Infections , 2011, Antimicrobial Agents and Chemotherapy.

[8]  N. Woodford,et al.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.

[9]  P. Gastmeier,et al.  Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008 , 2010, Critical care.

[10]  C. Salgado,et al.  The association between antibiotic use and resistance: the role of secondary antibiotics , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  B. Murray,et al.  Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, The New England journal of medicine.

[12]  M. Battegay,et al.  Secular Trend and Risk Factors for Antimicrobial Resistance in Escherichia coli Isolates in Switzerland 1997–2007 , 2009, Infection.

[13]  M. Synnestvedt,et al.  Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae , 2009, Infection Control & Hospital Epidemiology.

[14]  C. Salgado,et al.  Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic-Resistant Gram-Negative Bacteria , 2009, Antimicrobial Agents and Chemotherapy.

[15]  Bala Hota,et al.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Anderson,et al.  Emergence of extended-spectrum beta-lactamase-producing Escherichia coli in community hospitals throughout North Carolina: a harbinger of a wider problem in the United States? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Kluytmans,et al.  Correlation between antibiotic use and resistance in a hospital: Temporary and ward-specific observations , 2009, Infection.

[18]  I. Kassis,et al.  Carbapenem Resistance Among Klebsiella pneumoniae Isolates Risk Factors, Molecular Characteristics, and Susceptibility Patterns , 2009, Infection Control & Hospital Epidemiology.

[19]  K. Kaier,et al.  The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. , 2009, The Journal of antimicrobial chemotherapy.

[20]  A. Pakyz,et al.  Trends in antibacterial use in US academic health centers: 2002 to 2006. , 2008, Archives of internal medicine.

[21]  Kelly D Peterson,et al.  National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. , 2008, American journal of infection control.

[22]  Gopi Patel,et al.  Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies , 2008, Infection Control & Hospital Epidemiology.

[23]  Arjun Srinivasan,et al.  Emergency department visits for antibiotic-associated adverse events. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Rodríguez-Baño,et al.  Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  J. S. Bradley,et al.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Yehuda Carmeli,et al.  Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality , 2007, Antimicrobial Agents and Chemotherapy.

[27]  Fotini C Chelvatzoglou,et al.  Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. , 2007, The Journal of antimicrobial chemotherapy.

[28]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[29]  W. Bilker,et al.  Risk Factors for and Impact of Infection or Colonization With Aztreonam-Resistant Pseudomonas aeruginosa , 2007, Infection Control & Hospital Epidemiology.

[30]  M. Falagas,et al.  Attributable mortality of Acinetobacter baumannii: no longer a controversial issue , 2007, Critical care.

[31]  W. Bilker,et al.  Impact of Different Methods for Describing the Extent of Prior Antibiotic Exposure on the Association Between Antibiotic Use and Antibiotic-Resistant Infection , 2007, Infection Control & Hospital Epidemiology.

[32]  Charles E McCulloch,et al.  Relaxing the rule of ten events per variable in logistic and Cox regression. , 2007, American journal of epidemiology.

[33]  R. Polk,et al.  Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  J. Burke,et al.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship , 2007 .

[35]  D. Nicolau,et al.  Impact of Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species on Clinical Outcomes and Hospital Costs: A Matched Cohort Study , 2006, Infection Control & Hospital Epidemiology.

[36]  S. Choi,et al.  Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. , 2006, Diagnostic microbiology and infectious disease.

[37]  P. Donnan,et al.  Effect of individual- and group-level antibiotic exposure on MRSA isolation: a multilevel analysis. , 2006, The Journal of antimicrobial chemotherapy.

[38]  W. Bilker,et al.  Comparison of Unit-Specific and Hospital-Wide Antibiograms Potential Implications for Selection of Empirical Antimicrobial Therapy , 2006, Infection Control & Hospital Epidemiology.

[39]  C. Ramsay,et al.  Systematic Review of Antimicrobial Drug Prescribing in Hospitals , 2006, Emerging infectious diseases.

[40]  P. Phelps,et al.  Evaluation of the defined daily dose method for estimating anti-infective use in a university hospital. , 2005, American Journal of Health-System Pharmacy.

[41]  R. Venezia,et al.  Risk factors associated with extended-spectrum β-lactamase-producing organisms at a tertiary care hospital , 2005 .

[42]  F. Mackenzie.  Antibiotic consumption in European hospitals. , 2005, Médecine et maladies infectieuses.

[43]  S. Choi,et al.  Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. , 2005, Microbial drug resistance.

[44]  Y. Carmeli,et al.  The Case-Case-Control Study Design: Addressing the Limitations of Risk Factor Studies for Antimicrobial Resistance , 2005, Infection Control & Hospital Epidemiology.

[45]  S. Cosgrove,et al.  The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges , 2005, Infection Control & Hospital Epidemiology.

[46]  Outi Lyytikäinen,et al.  Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002 , 2004, Emerging infectious diseases.

[47]  D. Talon,et al.  Methodological validation of monitoring indicators of antibiotics use in hospitals , 2004, Pharmacy World and Science.

[48]  Y. Carmeli,et al.  Fluoroquinolones and the Risk for Methicillin-resistant Staphylococcus aureus in Hospitalized Patients , 2003, Emerging infectious diseases.

[49]  J. Bakken,et al.  The value of an infectious diseases specialist. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  J. Viel,et al.  Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  J. Quinn,et al.  Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. , 2003, JAMA.

[52]  J. Burke,et al.  Infection control - a problem for patient safety. , 2003, The New England journal of medicine.

[53]  R A Weinstein,et al.  The effect of renal dysfunction on antimicrobial use measurements. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  M. Lipsitch,et al.  Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  M. Lipsitch,et al.  Antimicrobial Use and Antimicrobial Resistance: A Population Perspective , 2002, Emerging Infectious Diseases.

[56]  Y. Carmeli,et al.  Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  W. Bilker,et al.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  H. Endtz,et al.  Prevalence and Determinants of Fecal Colonization with Vancomycin-Resistant Enterococcus in Hospitalized Patients in The Netherlands , 2000, Infection Control & Hospital Epidemiology.

[59]  I. Gould.  A review of the role of antibiotic policies in the control of antibiotic resistance. , 1999, The Journal of antimicrobial chemotherapy.

[60]  D. Gerding,et al.  Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. , 1997, Infection control and hospital epidemiology.

[61]  T. Horan,et al.  Definitions of key terms used in the NNIS System. , 1997, American journal of infection control.

[62]  J. Concato,et al.  Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. , 1995, Journal of clinical epidemiology.

[63]  P Peduzzi,et al.  Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. , 1995, Journal of clinical epidemiology.

[64]  J K McLaughlin,et al.  Selection of controls in case-control studies. II. Types of controls. , 1992, American journal of epidemiology.

[65]  S Greenland,et al.  Ecological bias, confounding, and effect modification. , 1989, International journal of epidemiology.

[66]  M. T. Parker,et al.  Methicillin resistance in staphylococci. , 1963, Lancet.

[67]  M. Barber,et al.  Bacteriophage Types in Penicillin-resistant Staphylococcal Infection , 1949, British medical journal.

[68]  J. Vincent.  Does microbial resistance matter? , 2011, The Lancet. Infectious diseases.

[69]  K. Mertens,et al.  Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. , 2011, The Lancet. Infectious diseases.

[70]  S. Janković,et al.  Resistance rates of Pseudomonas aeruginosa and Acinetobacter species causing ventilator-associated pneumonia do not always correlate with utilisation of antibiotics. , 2011, Journal of Hospital Infection.

[71]  K. de With,et al.  Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. , 2005, The Journal of antimicrobial chemotherapy.

[72]  A. Voss,et al.  Methicillin-ResistantStaphylococcus aureus in Europe , 2005, European Journal of Clinical Microbiology and Infectious Diseases.